Intellectual Product
After Incyte’s commercial buy, Novartis shells out 2.7B for cancer specialist MorphoSys
Importal, MorphoSys, Acquisition (action), Incyte
UPDATE: Vertex beats own record in cystic fibrosis as next-gen treatment goes up against Trikafta
Cystic Fibrosis, Trikafta, vanza, Vertex, next-gen, Records
Takeda Reports Lower Profits in Latest Quarter, Closes $300M Deal with Protagonist
Protagonist, profit, Takeda, Quarter, Report (document), earnings, Takeda’s
Novo Nordisk Gets 2023 Profit Beat Fueled by Ozempic, Wegovy Sales Spike
Nordisk, Ozempic, Constant – dosing instruction fragment, exchange rate
FDA rejects Defender’s motion sickness treatment
United States Food and Drug Administration, Safety, Effectiveness
Lonza closes plant in China but CDMO’s sales signal an uptick in industry
Plants, China, Signal, Industry, Congestive heart failure
Fake versions of Novo Nordisk’s Ozempic linked to 3 dangerous hypoglycemia cases in US: Reuters
Hypoglycemia, Case (situation), Ultrasonography, Nordisk’s, United States Food and Drug Administration
Sarepta shares PhII data for next-gen exon skipping drug, but regulatory pathway is unclear
Regulatory Pathway, Sarepta, next-generation exon-skipping drug, United States Food and Drug Administration, Approved, Muscular Dystrophy, Duchenne, gene therapy, Sarepta’s gene therapy